| Current State of Immunotherapy for Treatment of Glioblastoma |
45 |
| Use of Immune Checkpoint Inhibitors in Mesothelioma |
19 |
| Targeted Therapies for Triple-Negative Breast Cancer |
17 |
| Update on PARP Inhibitors in Breast Cancer |
16 |
| Epithelioid Hemangioendothelioma: Update on Diagnosis and Treatment |
16 |
| Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence |
15 |
| Review of Immune Therapies Targeting Ovarian Cancer |
15 |
| Update on the Treatment of Early-Stage Triple-Negative Breast Cancer |
15 |
| Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review |
13 |
| When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer? |
12 |
| Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading |
12 |
| Current and Future Directions for Angiosarcoma Therapy |
12 |
| Advanced Imaging Modalities to Monitor for Cardiotoxicity |
11 |
| Second Malignancies after Hematopoietic Stem Cell Transplantation |
11 |
| Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer |
11 |
| Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer |
11 |
| Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape |
10 |
| Radiation-Related Alterations of Taste Function in Patients With Head and Neck Cancer: a Systematic Review |
10 |
| The Role of CDK4/6 Inhibitors in Breast Cancer |
10 |
| Targeted Therapy and Immune Therapy for Small Cell Lung Cancer |
10 |
| Updates on Management of Adult Medulloblastoma |
10 |
| Head and Neck Cancer Survivorship Care: A Review of the Current Guidelines and Remaining Unmet Needs |
10 |
| Diagnosis and Management of Acral Lentiginous Melanoma |
10 |
| Peptide Receptor Radiotherapy: Current Approaches and Future Directions |
10 |
| Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review |
9 |
| Promising New Agents for Colorectal Cancer |
9 |
| Metastatic Colorectal Cancer to the Peritoneum: Current Treatment Options |
9 |
| Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma |
9 |
| Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC |
9 |
| Systemic Treatment for Adults with Synovial Sarcoma |
9 |
| Polycythemia Vera |
9 |
| The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions |
9 |
| Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer |
9 |
| First-Line Therapy for Metastatic Soft Tissue Sarcoma |
8 |
| The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer |
8 |
| Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer |
8 |
| Epidemiology of Head and Neck Squamous Cell Carcinomas: Impact on Staging and Prevention Strategies |
8 |
| Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma |
7 |
| The Role of Circulating Tumor DNA in Renal Cell Carcinoma |
7 |
| A Second Course of Radiotherapy in Patients with Recurrent Malignant Gliomas: Clinical Data on Re-irradiation, Prognostic Factors, and Usefulness of Digital Biomarkers |
7 |
| Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches |
6 |
| Targeted Therapy and Immunotherapy for Melanoma in Japan |
6 |
| New Concepts of Treatment for Patients with Myelofibrosis |
6 |
| Surgery for Abdominal Well-Differentiated Liposarcoma |
6 |
| Dermatoscopy of Neoplastic Skin Lesions: Recent Advances, Updates, and Revisions |
6 |
| Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies |
6 |
| Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia |
6 |
| Blastic Plasmacytoid Dendritic Cell Neoplasm |
6 |
| Eradicating Cancer Stem Cells: Concepts, Issues, and Challenges |
6 |
| Right Versus Left Colon Cancer: Resectable and Metastatic Disease |
6 |
